Photo: Getty Images
An experimental vaccine combination could be a big step forward in cancer treatment. A study finds a combination of Moderna's personalized melanoma vaccine and Merck & Co's immunotherapy Keytruda brought down the risk of recurrence or death by 44%.
The personalized vaccine is created using patients' tumors and healthy tissue and can be made in around eight weeks.